Can owning Aptose Biosciences Inc. (NASDAQ:APTO) haunt you?


Aptose Biosciences Inc. (NASDAQ:APTO) has posted results for the last fiscal year, recording EPS of $-0.97. For this year, EPS is anticipated to grow -19.00% over the preceding year, while next year’s EPS is predicted to increase 41.30%.

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend. The market is approaching overbought territory. Be watchful of a trend reversal.

Recently, Aptose Biosciences Inc. (NASDAQ:APTO) reported that for the previous five years, EPS at Aptose Biosciences Inc. has increased 11.80%, while rise sales have surged -% over the same period.

Shares of Aptose Biosciences Inc. are now trading at $1.56, giving it market cap of $29.78M. Over the last 12 months, shares of Aptose Biosciences Inc. have risen to maximum of $-55.43% and declined to a minimum of $100.00%.

The stock’s beta, which measures volatility, is 1.65. For the purpose of clarity, note that a beta of less than 1 implies that a stock is less volatile versus the overall market, while a beta over 1 indicates a stock is more volatile over the market.

Aptose Biosciences Inc. shows 20-Day Simple Moving Average of $45.32% and 50-Day Simple Moving Average of $50.81%. The 200-Day SMA is $18.01%.

The stock’s weekly performance is 51.46% while its monthly performance is 44.44%. Year-to-date the equity has moved 12.23% compared to a performance of -43.27% over the preceding 12 months.

Aptose Biosciences Inc. has witnessed 0.00% insider transactions, showing insider ownership of 20.40%. That compares to 35.10% ownership by institutional investors after 3.88% institutional transactions.

while return on assets for the equivalent period is -146.40%. Return on equity for the previous 12 months, on the other hand, is -174.80%.

Aptose Biosciences Inc. has RSI (Relative Strength Index) of 80.30.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS.TO), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company’s annual meeting of shareholders held today, June 6, 2017 (the “Meeting”).